Michael Camilleri1. 1. Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota 55905, USA. camilleri.michael@mayo.edu
Abstract
PURPOSE OF REVIEW: To assess the role of serotonin and its control in the manifestations and treatment of lower functional gastrointestinal disorders. RECENT FINDINGS: Recent literature has explored several novel concepts in the association of serotonin and symptoms, alterations in tissue levels of serotonin and its reuptake protein, aspects of the genetic determinants of serotonergic function (particularly 5-HTTLPR) and its relationship to gastrointestinal motor and sensory functions, and novel serotonergic agents used in therapy of lower functional gastrointestinal disorders. The most consistent findings are the increase in plasma 5-hydroxytryptamine (5-HT) in diarrheal diseases and reduction in constipation. The serotonin transporter in platelets has an impact on the circulating level of 5-HT. Meta-analysis shows that 5-HTTLPR genotype is not significantly associated with irritable bowel syndrome in Whites or Asians. New 5-HT3 antagonists and 5-HT4 agonists are efficacious and promise to provide relief for patients if they can pass regulatory hurdles. SUMMARY: Although the most relevant implication for clinical practice remains the evidence that serotonergic agents are efficacious in the treatment of chronic constipation, chronic diarrhea and irritable bowel syndrome, the role of genetic control of 5-HT and its receptors is the subject of ongoing research, and is likely to enhance understanding of the mechanisms and treatment of these diseases.
PURPOSE OF REVIEW: To assess the role of serotonin and its control in the manifestations and treatment of lower functional gastrointestinal disorders. RECENT FINDINGS: Recent literature has explored several novel concepts in the association of serotonin and symptoms, alterations in tissue levels of serotonin and its reuptake protein, aspects of the genetic determinants of serotonergic function (particularly 5-HTTLPR) and its relationship to gastrointestinal motor and sensory functions, and novel serotonergic agents used in therapy of lower functional gastrointestinal disorders. The most consistent findings are the increase in plasma 5-hydroxytryptamine (5-HT) in diarrheal diseases and reduction in constipation. The serotonin transporter in platelets has an impact on the circulating level of 5-HT. Meta-analysis shows that 5-HTTLPR genotype is not significantly associated with irritable bowel syndrome in Whites or Asians. New 5-HT3 antagonists and 5-HT4 agonists are efficacious and promise to provide relief for patients if they can pass regulatory hurdles. SUMMARY: Although the most relevant implication for clinical practice remains the evidence that serotonergic agents are efficacious in the treatment of chronic constipation, chronic diarrhea and irritable bowel syndrome, the role of genetic control of 5-HT and its receptors is the subject of ongoing research, and is likely to enhance understanding of the mechanisms and treatment of these diseases.
Authors: Nicholas S Coleman; Stephen Foley; Simon P Dunlop; Johanna Wheatcroft; Elaine Blackshaw; Alan C Perkins; Gulzar Singh; Charles A Marsden; Geoffrey K Holmes; Robin C Spiller Journal: Clin Gastroenterol Hepatol Date: 2006-06-22 Impact factor: 11.382
Authors: Michael Camilleri; Christopher N Andrews; Adil E Bharucha; Paula J Carlson; Irene Ferber; Debra Stephens; Thomas C Smyrk; Raul Urrutia; Jeroen Aerssens; Leen Thielemans; Hinrich Göhlmann; Ilse van den Wyngaert; Bernard Coulie Journal: Gastroenterology Date: 2006-11-17 Impact factor: 22.682
Authors: E A Mayer; S Berman; S W G Derbyshire; B Suyenobu; L Chang; L Fitzgerald; M Mandelkern; L Hamm; B Vogt; B D Naliboff Journal: Aliment Pharmacol Ther Date: 2002-07 Impact factor: 8.171
Authors: Johannes Kapeller; Lesley A Houghton; Hubert Mönnikes; Jutta Walstab; Dorothee Möller; Heinz Bönisch; Barbara Burwinkel; Frank Autschbach; Benjamin Funke; Felix Lasitschka; Nikolaus Gassler; Christine Fischer; Peter J Whorwell; Wendy Atkinson; Catherine Fell; Karl J Büchner; Marco Schmidtmann; Ivo van der Voort; Anna-Sophia Wisser; Thomas Berg; Gudrun Rappold; Beate Niesler Journal: Hum Mol Genet Date: 2008-07-09 Impact factor: 6.150
Authors: Viola Andresen; Victor M Montori; Jutta Keller; Colin P West; Peter Layer; Michael Camilleri Journal: Clin Gastroenterol Hepatol Date: 2008-01-31 Impact factor: 11.382
Authors: Marco Zucchelli; Michael Camilleri; Anna Nixon Andreasson; Francesca Bresso; Aldona Dlugosz; Jonas Halfvarson; Leif Törkvist; Peter T Schmidt; Pontus Karling; Bodil Ohlsson; Richard H Duerr; Magnus Simren; Greger Lindberg; Lars Agreus; Paula Carlson; Alan R Zinsmeister; Mauro D'Amato Journal: Gut Date: 2011-06-02 Impact factor: 23.059
Authors: Ahsan F Bairam; Mohammed I Rasool; Fatemah A Alherz; Maryam S Abunnaja; Amal A El Daibani; Saud A Gohal; Katsuhisa Kurogi; Yoichi Sakakibara; Masahito Suiko; Ming-Cheh Liu Journal: Biochem Pharmacol Date: 2018-03-08 Impact factor: 5.858